348 related articles for article (PubMed ID: 19162103)
1. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
2. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
4. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
5. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals.
Mutwiri G
Vet Immunol Immunopathol; 2012 Jul; 148(1-2):85-9. PubMed ID: 21700345
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
7. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.
Wilson KD; de Jong SD; Tam YK
Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo.
Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F
Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498
[TBL] [Abstract][Full Text] [Related]
10. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
12. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.
Heikenwalder M; Polymenidou M; Junt T; Sigurdson C; Wagner H; Akira S; Zinkernagel R; Aguzzi A
Nat Med; 2004 Feb; 10(2):187-92. PubMed ID: 14745443
[TBL] [Abstract][Full Text] [Related]
13. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).
McCluskie MJ; Cartier JL; Patrick AJ; Sajic D; Weeratna RD; Rosenthal KL; Davis HL
Antiviral Res; 2006 Feb; 69(2):77-85. PubMed ID: 16377001
[TBL] [Abstract][Full Text] [Related]
14. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo.
Zhang L; Tian X; Zhou F
Int Immunopharmacol; 2007 Dec; 7(13):1732-40. PubMed ID: 17996683
[TBL] [Abstract][Full Text] [Related]
15. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
17. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
[TBL] [Abstract][Full Text] [Related]
19. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration.
von Beust BR; Johansen P; Smith KA; Bot A; Storni T; Kündig TM
Eur J Immunol; 2005 Jun; 35(6):1869-76. PubMed ID: 15909311
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
